<DOC>
	<DOCNO>NCT00568009</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multi-center , sequential cohort study subject congestive heart failure ( CHF ) impair renal function stable furosemide treatment ( Â³ 40 mg daily ) . A total 50 subject randomize increase dose level SLV320 placebo sequential fashion .</brief_summary>
	<brief_title>Study Evaluate Effect SLV320 Addition Chronic Furosemide Treatment Renal Function Subjects With Congestive Heart Failure Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<criteria>Male female subject age 18 to85 year give write informed consent . Subjects must history chronic , symptomatic , New York Heart Association ( NYHA ) Class IIIII CHF impair renal function ( baseline eGFR 20 75 mL/min/1.73m2 ) . Congestive heart failure diagnose least 3 month Visit 1 ( Day 1 ) subject chronic treatment furosemide ( 40 mg daily ) least 3 week Visit 1 ( Day 1 ) . Subjects must stable dos individually optimize medication regimen least 4 week Visit 1 ( Day 1 ) . Any history convulsive disorder preconvulsive state risk convulsive disorder preconvulsive state ( example past brain trauma , abuse alcohol ) lead exclusion study . Females childbearing potential use specified contraception , subject malignant tumor short life expectancy , subject know severe reaction drug subject bilateral renal artery stenosis exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Impaired Renal Function</keyword>
</DOC>